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BACKGROUND: Cardiac arrest is a tragic event that causes 1 death 
roughly every 90 seconds worldwide. Survivors generally undergo a 
workup to identify the cause of arrest. However, 5% to 10% of cardiac 
arrests remain unexplained. Because cardiac arrhythmias underlie most 
cardiac arrests and increasing evidence strongly supports the involvement 
of autoantibodies in arrhythmogenesis, a large-panel autoantibody 
screening was performed in patients with cardiac arrest.
METHODS: This is an observational, cross-sectional study of patients 
from the Montreal Heart Institute hospital cohort, a single-center 
registry of participants. A peptide microarray was designed to screen 
for immunoglobulin G targeting epitopes from all known cardiac ion 
channels with extracellular domains. Plasma samples from 23 patients 
with unexplained cardiac arrest were compared with those from 22 
patients with cardiac arrest cases of ischemic origin and a group of 29 
age-, sex-, and body mass index–matched healthy subjects. The false 
discovery rate, least absolute shrinkage and selection operator logistic 
regression, and random forest methods were carried out jointly to find 
significant differential immunoglobulin G responses.
RESULTS: The autoantibody against the pore domain of the L-type 
voltage-gated calcium channel was consistently identified as a biomarker 
of idiopathic cardiac arrest (P=0.002; false discovery rate, 0.007; 
classification accuracies ≥0.83). Functional studies on human induced 
pluripotent stem cell–derived cardiomyocytes demonstrated that the anti–
L-type voltage-gated calcium channel immunoglobulin G purified from 
patients with idiopathic cardiac arrest is proarrhythmogenic by reducing 
the action potential duration through calcium channel inhibition.
CONCLUSIONS: The present report addresses the concept of 
autoimmunity and cardiac arrest. Hitherto unknown autoantibodies 
targeting extracellular sequences of cardiac ion channels were detected. 
Moreover, the study identified an autoantibody signature specific to 
patients with cardiac arrest.
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Cardiac arrest is a tragic event that causes 1 death roughly every 90 seconds worldwide.1,2 Structural heart disease is the main culprit and predisposes 
the patient to potentially life-threatening ventricular 
tachyarrhythmias (VTs).1,2 In the absence of structural 
heart disease, the differential diagnosis includes pri-
mary electrical disorders (eg, long-QT syndrome, short-
QT syndrome, Brugada syndrome, catecholaminergic 
polymorphic VT).3 Despite the many advances in diag-
nostic tools ranging from cardiac imaging studies and 
coronary angiography to genetic testing, 5% to 10% 
of cardiac arrests remain unexplained.2,4–6 In the past 
decade, emerging data have suggested the involve-
ment of autoantibodies in the pathogenesis of cardiac 
arrhythmias.7 Nevertheless, to the best of our knowl-
edge, an autoantibody profile of cardiac arrest has not 
been systematically investigated so far in a controlled 
study. In the search for arrhythmogenic autoantibodies, 
a large-panel autoantibody screening was performed in 
patients who survived a cardiac arrest of unknown ori-
gin and compared with that from patients with cardiac 
arrest of ischemic origin and healthy subjects. A special 
emphasis was placed on autoantibodies targeting car-
diac ion channels.
METHODS
The data that support the findings of this study are available 
from the corresponding author on reasonable request.
Study Design
This study is reported in accordance with the guidelines from 
the Strengthening the Reporting of Observational Studies in 
Epidemiology Consortium.8 Any member of the Montreal 
Heart Institute (MHI) community, including patients with 
or at risk for heart disease, individuals attending the hospi-
tal for routine blood tests, family members of patients, and 
employees, may participate in this cohort. Between May 2007 
and November 2018, among 16 762 participants of the MHI 
hospital cohort, 74 patients were identified for the present 
study according to the following selection criteria: survivors 
of cardiac arrest who underwent a comprehensive cardiac 
workup, notably a detailed history, ECG, transthoracic echo-
cardiography, cardiac magnetic resonance imaging when 
indicated, and coronary angiography. Cardiac arrest was 
defined as “cessation of cardiac activity such that the victim 
becomes unresponsive, with no normal breathing and no 
signs of circulation,” in accordance with the current guide-
lines but including only cardiac arrest resulting from shock-
able rhythm (ie, documented pulseless ventricular tachycardia 
or ventricular fibrillation).9 The scope of the present study 
thus involved cases of in-hospital and out-of-hospital cardiac 
arrest. Patients with autoimmune diseases, immunodeficient 
conditions, or malignancies were excluded from the study. 
Twenty-two patients meeting the aforementioned inclusion 
and exclusion criteria had a cardiac arrest subsequent to 
myocardial ischemia (referred to as ischemic cardiac arrest) 
as evidenced by coronary angiography. Twenty-three cases 
of cardiac arrest were of unknown origin. The patients were 
classified as having idiopathic cardiac arrest when the cardiac 
arrest was unexplained and when the patients did not have 
any structural heart disease (excluded by echocardiography 
or cardiac magnetic resonance imaging), coronary artery dis-
ease (excluded by coronary angiography), or primary electric 
disorder (negative genetic testing). When appropriate, an epi-
nephrine and procainamide provocation test was performed 
in these patients but did not unmask any long-QT syndrome, 
catecholaminergic polymorphic VT, or Brugada syndrome. 
Targeted genetic testing was performed on the basis of 
phenotype detection and evaluated in accordance with the 
guidelines by the American College of Medical Genetics and 
Genomics.10 In addition, 29 age-, sex-, and body mass index–
matched healthy subjects (referred to as healthy) from the MHI 
hospital cohort were included in the autoantibody screening. 
They were considered to be in the healthy group when they 
had no medical condition, in particular no history of or known 
cardiac disease and a normal ECG and heart function (pre-
served left ventricular ejection fraction, no signs of ischemia 
on exercise electrocardiographic testing, stress echocardiog-
raphy, or myocardial scintigraphy). All participants provided 
written informed consent to participate in the MHI hospital 
cohort. The study protocol was approved by the local ethics 
committee of the MHI. The study was conducted in accor-
dance with the Declaration of Helsinki and the guidelines of 
Good Clinical Practice issued by the International Conference 
on Harmonization.
Antigenic Epitopes
Cardiac ion channels are composed of a number of mem-
brane-spanning, pore-forming proteins. Because the extra-
cellular domains are naturally accessible, they are putative 
recognition sites for circulating antibodies. Peptides from 
extracellular domains of cardiac ion channels were there-
fore exclusively selected, as done previously for the KCNQ1 
study.11,12 In the present de novo search for autoantibodies, a 
peptide library consisting of epitopes derived from all existing 
cardiac ion channels was generated, including the sodium, 
Clinical Perspective
What Is New?
• The present study explored the autoantibody pro-
file of patients with idiopathic and ischemic cardiac 
arrest compared with healthy control subjects.
• New autoantibodies targeting cardiac ion channels 
were detected.
• Anti–L-type voltage-gated calcium channel autoan-
tibodies are linked to idiopathic cardiac arrest.
• Anti–TWIK-related potassium channel 1 autoanti-
bodies are found in patients with ischemic cardiac 
arrest and healthy control subjects.
What Are the Clinical Implications?
• Potential immunoglobulin G biomarkers for cardiac 
arrest were identified.
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calcium, potassium channels, accessory subunits (minimal 
potassium channel subunit, minimal potassium channel sub-
unit–related peptide), and transient receptor potential chan-
nels. Additional antigenic peptides from G-protein–coupled 
receptors (M2-muscarinic, β1- and β2-adrenergic receptors) 
were included because they were described previously in the 
literature in the context of VT.7 To ascertain the antigenicity of 
the epitope selected, all sequences were analyzed beforehand 
with the Kolaskar and Tongaonkar method13 and with the 
Support Vector Machine integrated with the tripeptide simi-
larity and propensity scores (http://sysbio.unl.edu/SVMTriP).14
PEPperMAP Immunoglobulin G Profiling 
Against 100 Selected Peptides
Figure  1A provides an overview of the peptide microarray 
assay. Plasma samples were collected from all participants and 
screened for immunoglobulin G (IgG). Based on the peptides 
of interest, a peptide library (14–20 amino acid lengths) was 
synthesized (Table I in the Data Supplement) and translated 
into PEPperCHIP Custom Peptide Microarray chips in duplicate 
(PEPperPRINT GmbH, Heidelberg, Germany). In addition to the 
selected cardiac ion channel peptide sequences (Table I in the 
Data Supplement), the peptide microarrays were framed by 
influenza hemagglutinin (YPYDVPDYAG, 15 spots) and polio 
virus (KEVPALTAVETGAT, 16 spots) control peptides. Peptide 
microarrays were washed with 1× PBS with 0.05% Tween 
20 (3× for 1 minute) after each incubation step. Thirty min-
utes before the first assay, Rockland blocking buffer MB-070 
was applied. Plasma samples were incubated for 16 hours at 
4°C (shaking at 140 rpm) at a dilution of 1:30 in incubation 
buffer (ie, washing buffer with 10% blocking buffer). Goat 
anti-human IgG (Fc) DyLight800 (1:5000, 45 minutes at room 
temperature [RT]) served as secondary antibody, and the fol-
lowing control antibodies were used: mouse monoclonal anti-
hemagglutinin (12CA5) DyLight800 (1:2000, 45 minutes at 
RT). High-definition images from the microarrays were then 
acquired with the LI-COR Odyssey Imaging System (scanning 
offset, 0.65 mm; resolution, 21 µm; scanning intensities, 7/7) 
using wavelengths of 700 nm (red channel, for specific IgG 
signal quantification) and 800 nm (green channel). For qual-
ity control, 1 peptide microarray was incubated with second-
ary goat anti-human IgG (Fc) DyLight680 antibody (1:5000) 
and control mouse monoclonal anti-hemagglutinin (12CA5) 
DyLight800 antibody (1:2000) for 45 minutes at RT to analyze 
background interactions with the 100 different peptides of the 
microarray. At scanning intensities of 7/7 (red/green), no back-
ground interaction of the secondary or control antibodies with 
the printed peptides was observed, even on significant increase 
of brightness and contrast (Figure I in the Data Supplement).
Microarray Data Analysis
Data analysts from PEPperPRINT GmbH were blinded to the 
study design. Microarray image analysis was performed with 
the PepSlide Analyzer. The software algorithm breaks down 
fluorescence intensities of each spot into raw foreground 
and background signal and calculates averaged median 
foreground intensities and spot-to-spot deviations of spot 
duplicates. On the basis of the averaged median foreground 
intensities, an intensity map was generated, and interactions 
in the peptide map were highlighted by an intensity color 
code with red for high and white for low spot intensities. A 
maximum spot-to-spot deviation of 40% was tolerated; oth-
erwise, the corresponding intensity value was zeroed. To iden-
tify the prevailing IgG in the plasma samples, the averaged 
and corrected intensity values were sorted by decreasing spot 
intensities. The averaged spot intensities of the assays were 
further plotted with the plasma samples against the microar-
ray content from right on top to left on bottom in a row-wise 
manner to visualize overall spot intensities and signal-to-noise 
ratios. The intensity plots were correlated with peptide and 
intensity maps and with visual inspection of the microarray 
scans to identify IgG responses of the samples.
IgG Purification
The plasma samples from all patients with idiopathic car-
diac arrest were pooled together. Affinity chromatography 
using a sulfhydryl-reactive agarose matrix coupled to the 
DFDNVLAAMMALFTVSTFEG peptide with an N-terminal 
cysteine (Peptide Specialty Laboratories GmbH, Heidelberg, 
Germany) was used to purify IgG autoantibodies from the 
plasma. To this end, the affinity chromatography column 
(Peptide Specialty Laboratories GmbH) was loaded with the 
pooled plasma from patients with idiopathic cardiac arrest 
(diluted 1:1 with 1× PBS) for 4 hours at 4°C with slow rota-
tion. The total effluent was then run through the column twice 
before 3 washing steps with 1× PBS followed by 2 washing 
steps with 10 mmol/L Na-phosphate (pH 6.8). The antibodies 
were eluted from the column with Pierce IgG Elution Buffer 
(ThermoFisher Scientific, Zug, Switzerland) and collected in 
2 mol/L K2HPO4. The solution containing the IgG was then 
replaced by 1× PBS using diafiltration with the Amicon Ultra 
15 filter device (nominal molecular weight limit, 50 kDa; 
Merck & Cie, Schaffhausen, Switzerland). The IgG concentra-
tion of the eluate was then determined with a bicinchoninic 
acid assay (QuantiPro BCA Assay Kit, Sigma Aldrich GmbH, 
Buchs, Switzerland).
Human Induced Pluripotent Stem Cell–
Derived Cardiomyocyte Culture and 
Preparation
Human induced pluripotent stem cell-derived ventricular car-
diomyocytes (hiPSC-CMCs) were obtained from Ncardia BV 
(Pluricyte, Leiden, the Netherlands) and cultured according to 
manufacturer’s guidelines. Briefly, cryovials of hiPSC-CMCs 
were thawed by placing in an incubator at 37°C for 4 min-
utes before being transferred into a 50-mL tube. The vial was 
then rinsed with 1 mL Pluricyte Cardiomyocyte Medium, and 
the cell suspension (drop-wise) was immersed with 4.7 mL 
Pluricyte Cardiomyocyte Medium. After a centrifugation step 
at 250g for 3 minutes, the cells were resuspended in fresh 
Pluricyte Cardiomyocyte Medium and plated with a density 
of 250.000/cm2 on Petri dishes coated with Corning Matrigel 
(VWR, Dietikon, Switzerland) diluted 1:100 in DMEM/F-12 
(STEMCELL Technologies, Cologne, Germany). HiPSC-CMCs 
were maintained in Pluricyte Cardiomyocyte Medium and 
incubated at 37°C/5% CO2. The culture medium was changed 
every other day. All electrophysiological measurements were 
performed between days 7 and 14 at RT.
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Whole-Cell Patch Clamp Recording in 
hiPSC-CMCs
Whole-cell patch clamp experiments were performed with 
the EPC-10 amplifier controlled by PATCHMASTER (HEKA 
Elektronik GmbH, Lambrecht, Germany) to record action 
potentials on spontaneously beating cardiomyocytes and the 
calcium current, ICa, at RT. The external patch solution used 
to record cardiac action potentials under current-clamp mode 
was composed of (mmol/L) 140 NaCl, 5 KCl, 1 MgCl2, 10 
HEPES, 1.8 CaCl2, and 10 glucose (pH 7.4 adjusted with NaOH). 
Borosilicate glass pipettes (Harvard Apparatus, Holliston, 
MA) with tip resistances of 2 to 4 MΩ were filled with inter-
nal solution (mmol/L): 110 K+aspartate, 20 KCl, 1 MgCl2, 5 
Mg2+ATP, 0.1 Li+GTP, 10 HEPES, 5 Na+phosphocreatine, 0.05 
EGTA (pH adjusted to 7.3 with KOH), and amphotericin B 
(200 µg/ml, AppliChem GmbH, Darmstadt, Germany). To 
record ICa currents, the following extracellular solution was 
used (mmol/L): 130 N-methyl-glucamine, 5 CsCl, 2 CaCl2, 
1.2 MgCl2, 10 HEPES, and 5 glucose, titrated to pH 7.4 with 
CsOH. Borosilicate glass capillaries (Harvard Apparatus) with 
tip resistances of 5 to 8 MΩ were filled with internal solution 
composed of (mmol/L) 60 CsCl, 70 Cs-aspartate, 1 MgCl2, 
10 HEPES, 11 EGTA, and 5 Mg2+ATP, adjusted to pH 7.2 with 
CsOH. ICa was elicited with a holding potential of −80 mV, a 
250-millisecond depolarization step to −40 mV (to isolate L- 
from T-type ICa), followed by 300-millisecond test pulses (at 0.2 
Hz) to voltages between −50 and 30 mV in 10-mV increments. 
Membrane potentials were corrected for a liquid junction 
potential of 12.4 mV. Whole-cell currents were low-pass fil-
tered at 2.9 kHz and sampled at 4 kHz. The effect of purified 
anti–L-type voltage-gated calcium channel (Cav1.2) IgG (0.66 
µg/mL; incubation, 24 hours) on hiPSC-CMCs was compared 
with cells under control condition. In addition, a peptide 
competition assay was performed to validate the specificity of 
the IgG. The antibodies were neutralized through preincuba-
tion with an excess of DFDNVLAAMMALFTVSTFEG peptide 
(Peptide Specialty Laboratories GmbH) that corresponds to 
the epitope recognized by the antibody (antibody-to-peptide 
ratio, 1:10). Patch clamp data analyses were performed with 
FITMASTER (HEKA Elektronik GmbH).
Statistical Analysis
The statistical analysis of microarray data was performed by 
statisticians from PEPperPRINT GmbH. The median intensity 
values of all peptides were background corrected and either 
log2 transformed for better visualization of the microarray 
data or variance-stabilizing normalized for 2-class t tests.15 
Heat maps were generated with RStudio software (version 
1.2.1335, RStudio, Inc, Boston, MA) to provide an over-
view of general similarities and differences of IgG responses 
between the groups. Pair-wise comparisons were based on 
2-class t tests of the IgG responses of the idiopathic and isch-
emic cardiac arrest groups against the healthy group and on 
a 2-class t test of the idiopathic cardiac arrest against the 
Figure 1. Schematic representation of the peptide microarray assay and general heat map of the immunoglobulin G (IgG) response profiles.
A, A step-by-step overview of the electrophysiology-oriented peptide microarray assay (eOM). More details are delineated in the Methods section. B, The heat map 
of 100 peptides analyzed for immunoreactivity across 74 plasma samples. Data were background corrected and log2 transformed. Fluorescence signal intensities 
of plasma samples from cardiac arrest groups and healthy individuals are shown. Peptide sequences on the y axis are plotted against the plasma samples on the x 
axis. BKCa indicates calcium-activated potassium channel; Cav, voltage-gated calcium channel; GPCR, G-protein–coupled receptor; HCN, hyperpolarization-activated 
cyclic nucleotide-gated cation channel; Kir, inward rectifier potassium channel; K2P, 2-pore domain potassium channel; Kv, voltage-gated potassium channel; MinK, 
minimal potassium channel subunit; MiRP, MinK-related peptides; Nav, voltage-gated sodium channel; and TRP, transient receptor potential channel.
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ischemic cardiac arrest group. The differences in fluorescence 
intensity between the respective groups were determined to 
reflect the overall intensity ratio. Two-sided values of P<0.05 
were considered the threshold for statistical significance of 
differential IgG responses. P values were further corrected 
for multiple testing error with 10% false discovery rate 
(FDR) using the Benjamini-Hochberg procedure.16 FDR is the 
expected proportion of type I errors in null hypothesis testing 
when multiple comparisons are conducted, as in the case of 
microarray assays. With a cutoff for significance FDR <0.10, 
<10% of the significant results would be false positives. All 
data were processed with the Statistical Utility for Microarray 
and Omics data software developed at the German Cancer 
Research Center in Heidelberg, Germany. To evaluate the 
efficiency of the panel of 100 peptides in the detection of 
idiopathic cardiac arrest and to develop IgG response-based 
classifiers for idiopathic cardiac arrest, least absolute shrink-
age and selection operator (LASSO) logistic regression and 
random forest machine learning were applied. For LASSO 
logistic regression and random forest analysis, the 74 plasma 
samples were split into 2 parts: 85% of data for training 
and 15% for testing. Inverse hyperbolic transformation was 
applied for the training and test data separately. The algo-
rithm was trained and fine-tuned to select the best/optimal 
model and further to predict and evaluate the model in the 
test data. Machine learning techniques were used to learn 
classifiers of idiopathic cardiac arrest, ischemic cardiac arrest, 
and healthy groups. Specifically, the 10-fold cross-validation 
LASSO with the R package glmnet was used (https://glmnet.
stanford.edu).17,18 In addition, as a second orthogonal tech-
nique, random forests from the caret package was used 
(https://CRAN.R-project.org/package=caret).19 Accuracies 
based on confusion matrices were calculated for both the 
LASSO logistic regression and random forest methods. With 
regard to patient data, continuous variables are expressed 
as mean±SD, whereas nonnormally distributed variables are 
reported as median±interquartile range and categorical data 
in percentage. One-way ANOVA and the Tukey multiple-
comparisons test were performed to compare the means of 
the continuous data. The χ2 and Fisher exact tests were used 
for categorical variables. To compare the patch clamp data 
between groups, 1-way ANOVA was used, followed by the 
Tukey multiple-comparisons test. For nonnormally distributed 
data, the Kruskal-Wallis test was adopted, followed by the 
Dunn multiple-comparisons test. Statistical analyses were per-
formed with GraphPad Prism 7 (GraphPad Software, Inc, La 
Jolla, CA), and a value of P<0.05 was used for testing signifi-
cance of potential clinical confounders.
RESULTS
Clinical Characteristics
Forty-five patients who survived a cardiac arrest (23 
idiopathic, 22 ischemic) and 29 healthy subjects were 
enrolled in the present study (Table). Most cardiac ar-
rest cases occurred out-of-hospital, whereas 4.3% of 
patients with idiopathic cardiac arrest and 27.3% of 
patients with ischemic cardiac arrest were in-hospital 
(Table). Patients with ischemic heart disease were 
predominantly male, and the left ventricular ejection 
fraction was, as expected, reduced compared with the 
other groups. The median time between the echocar-
diographic examination and the cardiac arrest was 6 
days (interquartile range, 8 days). There were no ab-
normalities on the ECG of the idiopathic cardiac arrest 
group (Table).20–22 Of note, case patients were deliber-
ately selected on the basis of a normal ECG in line with 
the definition of idiopathic cardiac arrest. Just as car-
diac ion channel mutation carriers can have a normal 
ECG, the presence of potentially arrhythmogenic au-
toantibodies and the absence of ECG features are not 
mutually exclusive. Provocative testing (pharmacologi-
cal challenge with epinephrine or procainamide) was 
performed in 8.7% of patients with idiopathic cardiac 
arrest and showed no electrocardiographic patterns 
diagnostic of long-QT syndrome, catecholaminergic 
polymorphic VT, or Brugada syndrome. Sixty-five per-
cent of patients with unexplained cardiac arrest were 
subjected to genetic testing that yielded no disease-
causing mutation.
Autoantibody Response Profiles
In the present study, a peptide microarray encompass-
ing 100 epitopes corresponding to 33 different cardiac 
autoantigens was used to determine specific IgG re-
sponses in patients. The median time elapsed between 
the plasma sampling and the cardiac arrest event was 
4 years (interquartile range, 10 years). As visualized on 
the general heat map, plasma samples from each pa-
tient recognized different sets of peptides (Figure 1B). 
Most essentially, the existence of to-date unknown an-
tibodies was detected in both patients and healthy indi-
viduals. A common IgG response against the 2 peptides 
AEVDRVDSHFTSIPESFWWA (Kv1.7 protein) and PTGP-
NATESVQPMEGQEDEG (TRPV2 protein) could be found 
in nearly all samples.
Candidate IgG Biomarkers of Cardiac 
Arrest
Autoantibody signatures for patients with cardiac 
arrest were identified. First, the differential IgG re-
sponses were evaluated individually with a univari-
ate selection approach and ranked according to the 
differences that reflect the overall intensity ratio be-
tween the idiopathic cardiac arrest, ischemic cardiac 
arrest, and healthy groups. By controlling the FDR at 
10%, we identified 16 statistically significant differen-
tial IgG responses (Figure 2). To estimate the adjusted 
association of each IgG in the presence of the others 
and their joint IgG response, it is critical to analyze the 
differential IgG results with a multivariable approach. 
A multivariable modeling of biomarkers was there-
fore performed that included 10-fold cross-validation 
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LASSO logistic regression and random forest machine 
learning method as second orthogonal technique. 
Briefly, the LASSO logistic regression considers IgG 
responses with nonzero coefficients as potential bio-
markers, and the random forest method identifies 
them by ranking the IgG response according to the 
variable importance. In the present study, both algo-
rithms identified different sets of IgG response pat-
terns associated with the diagnosis of idiopathic car-
diac arrest compared with the ischemic cardiac arrest 
and healthy group (Figure II in the Data Supplement). 
The accuracy to determine the discriminatory per-
formance of each method in determining idiopathic 
cardiac arrest was also evaluated. Both methods per-
formed similarly. With an accuracy of 83% and 86%, 
the peptide-based microarray assay presents a high 
potential to distinguish idiopathic cardiac arrest from 
ischemic cardiac arrest and healthy control subjects 
respectively. Taken together, 1 single autoantibody 
was significantly upregulated in patients with idio-
pathic cardiac arrest compared with the ischemic 
cardiac arrest and healthy groups (P=0.002), persist-
ing after Benjamini-Hochberg correction (FDR, 0.007) 
and multivariable analyses (LASSO logistic regression 
and random forest): the autoantibody targeting the 
third extracellular loop of domain III (DIIIE3) of Ca
v1.2, 
a pore-forming region of the voltage-gated calcium 
channel (DFDNVLAAMMALFTVSTFEG; Figure  2). Af-
ter adjustment with the Benjamini-Hochberg post 
hoc analysis and multivariable modeling (consistent 
across both methods), autoantibodies recognizing 
the second pore of the TREK1 (TWIK-related potas-
sium channel 1) protein (DYVAGGSDIEYLDFYKPVVW) 
were strongly associated with cardiac arrest of isch-
emic origin and healthy control subjects (P<0.001; 
FDR <0.001; Figure 2). Plasma samples from healthy 
individuals presented high IgG responses with a com-
plex autoantibody pattern against cardiac ion chan-
nels. Overall, marked IgG reactivities were observed 
for potassium channels and other sequences of the 
Cav1.2 channel and the β1-adrenergic receptor com-
pared with the cardiac arrest population (Figure 2).
Table. Clinical Characteristics of the Study Population*
Idiopathic Cardiac 
Arrest
Ischemic Cardiac 
Arrest Healthy P Value§
Patients, n 23 22 29  
Age, mean±SD, y 53.5±14.7 55.9±10.9 48.6±14.9 0.15
Sex, % 0.30
  Male 56.5 72.7 51.7  
  Female 43.5 27.3 48.3  
BMI, mean±SD, kg/m2 29.9±6.2 29.6±6.6 27.9±5.0 0.42
Electrocardiographic parameters
  Rhythm, % sinus rhythm 100 86.4 100 0.10
  Heart rate, mean±SD, bpm 81.7±14.0 71.8±14.4 75.5±12.2 0.09
  PR, mean±SD, ms 168.1±21.1 177.5±34.3 155.6±13.4 0.02
  QRS, mean±SD, ms 95.7±10.3 96.6±15.7 87.3±9.3 0.01
  QT, mean±SD, ms 383.5±26.7 384.4±40.2 380.0±27.8 0.88
  Corrected QTBazett, mean±SD, ms 445.1±41.4 417.7±35.5 422.9±20.7 0.03
  Corrected QT,† mean±SD, ms 421.5±30.4 405.5±32.0 407.2±17.2 0.14
  Corrected QT,‡ mean±SD, ms 429.0±35.5 408.0±33.4 411.2±18.2 0.06
Echocardiographic parameters
  LVEF, mean±SD, % 60.0±5.3 47.3±16.5 62.5±3.6 <0.01
  LVEDD, mean±SD, mm 47.2±6.3 51.6±12.6 47.7±5.4 0.85
  IVSD, mean±SD, mm 9.4±2.2 10.3±1.9 9.8±1.7 0.46
  PWD, mean±SD, mm 9.2±1.8 9.0±1.2 8.7±1.8 0.80
BMI indicates body mass index; IVSD, interventricular septum diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, 
left ventricular ejection fraction; and PWD, posterior wall diameter.
*Values are mean±SD or number (percent). Age refers to the age at study enrollment.
†The QT interval was corrected with the Hodges formula [QTc=QT+1.75×(heart rate−60)] for QRS <120 milliseconds.
20
‡The QT interval was corrected with the method by Rautaharju et al21 [QTc=QT×(120+heart rate)/180] for QRS <120 
milliseconds. In the case of QRS ≥120 milliseconds in the ischemic cardiac arrest group, the following equation was used to 
adjust the QT interval: QTc=QT−155×(60/heart rate−1)−0.93×(QRS−139)+k(kmale=−22; kfemale=−34).
22 In the presence of atrial 
fibrillation, a weighted average modification of the Bazett formula was applied [QTc=QT/(RRmod)
1/2].11
§P values comparing idiopathic cardiac arrest vs ischemic cardiac arrest vs healthy group (ANOVA for normally distributed 
variables and Kruskal-Wallis test for nonnormally distributed data).
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Purification and Functional 
Characterization of the Candidate IgG
Next, the electrophysiological effects of anti-Cav1.2 an-
tibody targeting the DIIIE3 domain were explored on 
hiPSC-CMCs. Figure 3 shows representative action po-
tential and ICa current traces. The anti-Cav1.2 antibody 
significantly reduced the action potential duration at 
90% repolarization by 2.8-fold (control, 1178.0±169.3 
milliseconds versus anti-Cav1.2 IgG, 416.7±22.2 mil-
liseconds; P<0.001; Figure  3A) and depolarized the 
maximum diastolic potential (control, −71.8±3.2mV 
versus anti-Cav1.2 IgG, −50.3±4.9 mV; P=0.001). Of 
13 cells, the antibody induced an episode of alter-
nans, a typical arrhythmia substrate. The ICa current 
was recorded in hiPSC-CMCs. In accordance with the 
action potential duration shortening, the purified anti-
Cav1.2 antibody decreased ICa by 2-fold at the poten-
tial of −10 mV (P<0.001; Figure 3B). In addition, the 
presence of the blocking peptide corresponding to the 
DIIIE3 sequence abolished the effect of the antibody 
on cardiac action potential and ICa, thus confirming 
the IgG-specific response in vitro (Figure  3). The cell 
capacitance did not differ between groups (control, 
17.0±1.6 pF; anti-Cav1.2 IgG, 24.4±3.9 pF; anti-Cav1.2 
IgG+blocking peptide, 21.0±3.4pF; P=0.20). There was 
no autoantibody-associated shift of the half-maximal 
activation voltage (Figure III in the Data Supplement).
DISCUSSION
The present peptide microarray study compared the 
autoantibody-binding profiles of patients with cardiac 
arrest. Hitherto unknown autoantibodies targeting ex-
tracellular sequences of cardiac ion channels were de-
tected. The study identified an autoantibody signature 
specific to patients with cardiac arrest.
In previous studies, autoantibodies directed against 
cardiac antigens have been identified and linked to 
both tachyarrhythmias and bradyarrhythmias.7,23 For 
example, circulating autoantibodies recognizing the β1-
adrenergic receptor can be detected in 30% to 50% 
of patients with dilated cardiomyopathy and are inde-
pendent predictors of VT and sudden cardiac death.24 A 
high prevalence of anti–β2-adrenergic receptor autoan-
tibodies was found in patients with ventricular arrhyth-
mias.25 With cardiac ion channels as targets, autoanti-
bodies against the KCNH2 (hERG) channel have been 
associated with the long-QT syndrome in a patient with 
recurrent torsades de pointes tachycardia.26 Finally, au-
toantibodies targeting the L-type calcium channel were 
found in patients with dilated cardiomyopathy and have 
Figure 2. Cardiac arrest (CA)–specific antibody reactivities in plasma samples.
Listed are the peptides that demonstrated the highest immunoglobulin G (IgG) response in the idiopathic CA, ischemic CA, and healthy groups. The ranking was 
based on differences that reflect the overall intensity ratio between the groups. ANOVA compared the mean IgG responses from patients with idiopathic CA and 
ischemic CA and healthy control subjects. Reported are the respective P values and f ratio. The corresponding excerpt of the heat map is shown with the peptide 
sequences on the y axis plotted against the plasma samples on the x axis. *False discovery rate (FDR) correction for idiopathic CA vs healthy. †FDR correction for 
idiopathic CA vs ischemic CA. ‡FDR correction for ischemic CA vs healthy.
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been linked to a higher incidence of VT and cardiac ar-
rest.27 Of note, these latter autoantibodies recognize 
an epitope corresponding to an intracellular sequence 
of the L-type calcium channel. How immunoglobulins 
can access to and interact with an intracellular target 
remains uncertain.
The present study characterized the autoantibody 
signature associated with cardiac arrest. Autoantibod-
ies may perturb the flow of ions through the channels 
either by physically obstructing the conduction through 
the pore or by acting as an agonist (ligand mimicry or 
via allosteric modulation).11,12 As genetic mutations 
have taught us, a loss or gain of function of a certain 
channel can result in cardiac arrhythmias and presents 
the basis for a number of arrhythmia syndromes. With 
this hypothesis in mind, interest in screening patients 
for autoantibodies against a variety of antigenic epit-
opes of cardiac ion channels has become evident. The 
analyses demonstrated distinct patterns of autoanti-
body profiles. Using the FDR method, LASSO logistic 
regression, and random forest, the study identified 
IgGs targeting the peptide DFDNVLAAMMALFTVST-
FEG (Cav1.2 channel) as a potential biomarker linked 
to idiopathic cardiac arrest with accuracies of 83% 
Figure 3. Whole-cell patch clamp recordings in human induced pluripotent stem cell-derived ventricular cardiomyocytes (hiPSC-CMCs).
A, Representative action potential traces. The action potential duration was determined at 90% repolarization (APD90) for control cells (1178.0±169.3 milliseconds; 
n=16), in the presence of anti–L-type voltage-gated calcium channel (Cav1.2) immunoglobulin G (IgG; 416.7±22.2 milliseconds; n=13) vs anti-Cav1.2 IgG+blocking 
peptide (933.3±107.1 milliseconds; n=6). B, Representative ICa (control, 16.2pF; anti-Cav1.2 IgG, 22.5pF; anti-Cav1.2 IgG+blocking peptide, 21.3pF) current 
responses to a voltage step from −50 to 30 mV (see outlined voltage step stimulation protocol). Bottom, I-V relationships of control cells (n=9) and in the pres-
ence of anti-Cav1.2 IgG (n=8) and anti-Cav1.2 IgG+blocking peptide (n=5) are presented. ICa currents are expressed as densities normalized to cell capacitance. The 
respective mean±SEM values are displayed. P<0.05, control vs anti-Cav1.2 IgG. All measurements were performed at room temperature.
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and 86%. Antibodies targeting the DYVAGGSDIEYLD-
FYKPVVW (TREK1 channel) sequence could be distin-
guished across both multivariable modeling methods 
and had a significant univariable association with the 
healthy and the cardiac arrest population with underly-
ing ischemic heart disease. Because calcium channels 
form depolarizing inward currents that are critical for 
the plateau phase of the action potential, it is not sur-
prising that perturbations of their function can lead to 
cardiac arrhythmias.28 The target peptide DIIIE3 is lo-
calized at the ion selectivity and permeability filter of 
the calcium channel, a site where a missense mutation 
(CACNA1C-E1115K) has been related to the Brugada 
syndrome and sudden cardiac death.29,30 In the pres-
ent study, the existence of an autoantibody specifi-
cally targeting the pore region of the calcium channel 
is described. Moreover, the DIIIE3-targeted anti-Cav1.2 
antibodies reduce action potential duration by their cal-
cium channel-inhibiting effect in hiPSC-CMCs and de-
polarize the membrane potential, both arrhythmogenic 
substrates. Two-pore domain potassium channels are 
essential in mediating background outward currents in 
cardiomyocytes. Notably, TREK1 channels are important 
modulators of the repolarization phase of the action 
potential, and alterations in their function have been 
linked to VT.31 Autoantibodies targeting TREK1 have 
not been reported before. Future studies are warranted 
to determine the role of anti-TREK1 antibodies.
In the present study, healthy individuals demonstrat-
ed a complex profile of IgG autoantibodies directed 
against several cardiac antigens. The abundance and 
diversity of circulating autoantibodies imply that they 
may carry out some important but as yet unrecognized 
function. Boyden32 first introduced the term natural 
autoantibodies to describe the immune system, rec-
ognizing self-constituents in healthy persons. Natural 
autoantibodies are thought to play an important physi-
ological role, notably in the maintenance of tissue ho-
meostasis through the adaptive clearance of tissue and 
cell debris after degradation.33,34 Healthy individuals in 
the present study presented high IgG reactivities to the 
peptide sequence KGNYITYKDGEVDHPIIQPR of the L-
type calcium channel, only 7 amino acids upstream of 
the DIIIE3 autoantibody target of the idiopathic cardiac 
arrest population (DFDNVLAAMMALFTVSTFEG). The 
close proximity of the targets suggests the possibility 
of a competitive antagonistic interaction between both 
autoantibodies. Future studies are needed to verify 
this hypothesis attributing a protective role of auto-
antibodies directed against KGNYITYKDGEVDHPIIQPR. 
Contrary to expectation, a stronger IgG response di-
rected against the second extracellular loop of the β1-
adrenergic receptor was found in the healthy group. 
Anti–β1-adrenergic receptor autoantibodies have been 
described mainly in the context of dilated cardiomyop-
athies with proarrhythmogenic properties.25 However, 
they also have been detected in the healthy population, 
with the frequency of occurrence increasing with age.35 
Their role in healthy individuals is yet to be defined.
The advantage with peptide microarrays is the high-
throughput screening of plasma samples for IgG reac-
tivities against many peptides simultaneously. However, 
the findings of this study have to be seen in light of 
some limitations. Limitations of the assay are the fail-
ure to consider conformational epitopes, that is, the 
natively folded protein structure, and the respective 
affinity of the antibodies. Nevertheless, the identified 
antibody targeting the extracellular calcium channel 
epitope has shown functionality in blocking channel 
function. The role of the other autoantibodies detected 
in each patient population has not been investigated. 
Although patients with autoimmune disorders were ex-
cluded from the study, an assessment of patients’ signs 
and symptoms suggestive of autoimmune diseases 
was not performed after study inclusion. The number 
of idiopathic cardiac arrest cases in this study was rela-
tively small, an inherent problem in studies with strin-
gent inclusion and exclusion criteria for a condition for 
which plasma samples are rarely collected. Larger pa-
tient cohorts with follow-up studies will be important 
to better understand the peripheral antibody repertoire 
against cardiac ion channels. Most important, all the 
plasma samples of patients were obtained after the 
index event. Consequently, it cannot be excluded that 
the identified autoantibodies could have been gener-
ated as a result of cardiac arrest rather than being the 
cause of cardiac arrest. However, if cardiac arrest were 
to induce an autoimmune response, one would likely 
have expected to find similar IgG response profiles in 
cardiac arrest of ischemic and idiopathic origin. How 
the autoimmune mechanism is initiated and regulated 
remains largely unknown. Future studies are necessary 
to differentiate the role of the autoantibodies in car-
diac arrest, that is, to distinguish between preceding 
autoantibodies (and thus contributing to cardiac arrest) 
and autoantibodies generated in response to cardiac 
arrest. In addition, subsequent studies addressing the 
(protective?) role of autoantibodies targeting cardiac 
ion channels in the healthy will be of particular interest. 
A further limitation of the study is that only survivors of 
cardiac arrest were considered; that is, decedents were 
excluded from the autoantibody screening. The results 
are therefore subject to survivor bias. Nonetheless, the 
in vitro proarrhythmogenic properties of anti-Cav1.2 
autoantibodies from patients with idiopathic cardiac ar-
rest indicate that the IgG may have disease relevance.
Conclusions
The findings of the present study suggest that a distinct 
immunosignature distinguishes patients with aborted 
cardiac arrest from healthy control subjects.
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